Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
A single-arm, single-center, open label Phase 1 study of a 12-week course of Sofosbuvir
(SOF)/Velpatasvir (VEL) in 10 HCV-infected pregnant women 1 that will evaluate the plasma
pharmacokinetic parameters of SOF/VEL administered during pregnancy and compare them to those
of a historical cohort of nonpregnant women.
Phase:
Phase 1
Details
Lead Sponsor:
Catherine Chappell
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Gilead Sciences
Treatments:
Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir